New drug combo aims to shrink breast tumors before surgery, spare chemo
NCT ID NCT05069038
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether giving the drug palbociclib (Ibrance) together with hormone therapy (letrozole, plus goserelin for premenopausal women) before surgery can shrink early-stage hormone receptor-positive, HER2-negative breast tumors. The study enrolls 51 patients with stage IIA to IIIC disease. The goal is to improve surgical outcomes and offer a gentler alternative to chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Palbociclib (Ibrance) combined with letrozole and possibly goserelin
What this could lead to
If successful, this could offer a more effective, less toxic pre-surgery treatment option for early-stage hormone receptor-positive breast cancer, potentially reducing the need for chemotherapy.
What could go wrong
This is a small, early-phase (phase II) trial with only 51 participants, so results may not apply to all patients. Side effects like low white blood cell counts (neutropenia) are a known risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Unversity of Nebraska Medical Center
Omaha, Nebraska, 68198, United States